A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
The aim of the trial is to assess the benefit of adding high precision radiation therapy to chemotherapy and surgery for the treatment of pancreatic cancer.
Primary Sponsor
Australasian Gastro-Intestinal Trials Group (AGITG)
Collaborating Groups
AGITG, TROG and NHMRC CTC
Accrual Target
120
Trial Chairperson
Dr Andrew Oar, Gold Coast University Hospital
Trial Contact
MASTERPLAN@ctc.usyd.edu.au
Clinical Trial Registration
Related Post
October 18, 2022
NINJA Radiation Therapy Trial participant tells his journey to treatment
The journey to becoming the 200th participant for the
September 6, 2022
The gift that kept on giving
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
